Role of serotonin in central dopamine dysfunction

CNS Neuroscience and Therapeutics

Volumn 16, Issue 3, 2010, Pages 179-194

  Di Giovanni, Giuseppe ^a   Esposito, Ennio ^b   Di Matteo, Vincenzo ^b  

^a UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

5 HT receptors; Antidepressants; Antipsychotics; Dopaminergic function; Drug addiction; Mesocorticolimbic DA system; Microdialysis; Nigrostriatal DA system; Parkinson disease; Single cell recording

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AGOMELATINE; BEMESETRON; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; DOPAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IPSAPIRONE; LEVODOPA; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEFAZODONE; ONDANSETRON; PAROXETINE; SEROTONIN; SEROTONIN 3 RECEPTOR; SERTRALINE; TROPISETRON; UNINDEXED DRUG; VALPROIC ACID; VOLINANSERIN; ZACOPRIDE; ZONISAMIDE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAPHE NUCLEUS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; VENTRAL TEGMENTUM; ANIMAL; BRAIN; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DOPAMINE; HUMANS; SEROTONIN;

EID: 77952160143     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00135.x     Document Type: Review

References (169)

1. Dahlström A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. Part I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964 62 : 1 55.
2. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 1983 35 : 53 68.
3. Roth RH, Wolf ME, Deutch AY. Neurochemistry of midbrain dopamine systems. In : Meltzer HY, editor. Psychopharmacology: The third generation of progress.
4. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 1993 18 : 75 113.
5. White FJ. Synaptic regulation of mesocorticolimbic dopamine neurons. Annu Rev Neurosci 1996 19 : 405 436.
6. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 1991 71 : 155 234.
7. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988 85 : 5274 5278.
8. Koob GF. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992 13 : 177 184.
9. Salamone JD, Correa M, Farrar A, Mingote SM. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 2007 191 : 461 482.
10. Roth RH, Elsworth JD. Biochemical pharmacology of midbrain dopamine neurons. In : Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress.
11. Morrow BA, Elsworth JD, Zito C, Roth RH. Biochemical and behavioral anxiolytic-like effects of R(+) HA-966 at the level of the ventral tegmental area in rats. Psychopharmacology 1999 143 : 227 234.
12. Grace A, Bunney B. Dopamine. In : Rogawski MA, Barker JL, editors. Neurotransmitter action in the vertebrate nervous system.
13. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978 179 : 641 659.
14. Van Der Kooy D, Attori T. Dorsal raphé cells with collateral projections to the caudate-putamen and substantia nigra: A fluorescent retrograde double labeling study in the rat. Brain Res 1980 186 : 1 7.
15. Steinbush HWM. Serotonin-immunoreactive neurons and their projections in the CNS. In : Björklund A, Hökfelt T, Kuhar MJ, editors. Handbook of chemical neuroanatomy: Classical transmitter receptors in the CNS, Part II.
16. Hervé D, Pickel VM, Joh TH, Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res 1987 435 : 71 83.
17. Van Bockstaele EJ, Biswas A, Pickel VM. Topography of serotonin neurons in the dorsal raphé nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res 1993 624 : 188 198.
18. Van Bockstaele EJ, Cestari DM, Pickel VM. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: Potential sites for modulation of mesolimbic dopamine neurons. Brain Res 1994 647 : 307 322.
19. Moukhles H, Bosler O, Bolam JP, Vallée A, Umbriaco D, Geffard M, Doucet G. Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 1997 76 : 1159 1171.
20. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002 71 : 533 554.
21. Hoyer D, Clarke DE, Fozard JR, Harting PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994 46 : 157 203.
22. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999 38 : 1083 1152.
23. Samanin R, Garattini S. The serotonergic system in the brain and its possible functional connections with other aminergic systems. Life Sci 1975 8 : 1201 1209.
24. 1C receptors. J Pharmacol Exp Ther 1992 260 : 1361 1365.
25. Fibiger HC. Neurobiology of depression: Focus on dopamine. In : Gessa G, Fratta W, Pani L, Serra G, editors. Depression and mania: From neurobiology to treatment.
26. Brown AS, Gershon S. Dopamine and depression. J Neural Transm 1993 91 : 75 109.
27. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci 2001 22 : 229 232.
28. 2C receptors. Eur J Pharmacol 2003 480 : 151 162.
29. 2C receptors to multiple action of central serotonin systems. Eur J Pharmacol 2004 488 : 1 9.
30. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007 113 : 296 320.
31. Puglisi-Allegra S, Imperato A, Angelucci L, Cabib S. Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res 1991 554 : 217 222.
32. Cabib S, Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology 1996 128 : 331 342.
33. 2C receptor antagonist. CNS Drug Reviews 2000 6 : 195 205.
34. 2C receptors. Psychopharmacology 2000 150 : 45 51.
35. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998 37 : 265 272.
36. Baxter GS, Kennett GA, Blaney F, Blackburn T. 5-HT2 receptor subtypes: A family reunited? Trends Pharmacol Sci 1995 16 : 105 110.
37. 2C receptors in affective disorders. Exp Opin Invest Drugs 1998 7 : 1587 1599.
38. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993 231 : 223 229.
39. Jenck F, Moreau JL, Mutel V, Martin JR. Brain 5-HT1C receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1994 18 : 563 574.
40. Sampson D, Muscat R, Willner P. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology 1991 104 : 491 495.
41. Moreau JL, Bourson A, Jenck F, Martin JR, Mortas P. Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression. J Psychiatr Neurosci 1994 19 : 51 56.
42. Willner P. Animal models of depression: Validity and applications. In : Gessa G, Fratta W, Pani L, Serra G, editors. Depression and mania: From neurobiology to treatment.
43. Tanda G, Carboni E, Frau R, Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology 1994 155 : 285 288.
44. Tanda G, Bassareo V, Di Chiara G. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology 1996 123 : 127 130.
45. 1C receptor activation in rats. Psychopharmacology 1993 110 : 140 144.
46. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 1996 6 : 169 175.
47. 2C receptors and their atypical regulation properties. Life Sci 2003 72 : 2429 2449.
48. 2C receptor as a target for mood disorders. Expert Opin Ther Targets 2004 8 : 1 9.
49. 1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. Mol Pharmacol 1993 44 : 725 730.
50. /2receptor agonists and antagonists. Eur J Pharmacol 1993 244 : 1 5.
51. 2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J Neurochem 1997 69 : 1031 1038.
52. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 1995 116 : 1923 1931.
53. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 1995 281 : 255 261.
54. Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm: Gen Sec 1992 88 : 143 156.
55. Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 1998 46 : 547 554.
56. 2C receptors: A comparison with citalopram. Eur J Neurosci 2000 12 : 1079 1095.
57. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003 306 : 954 964.
58. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005 48 : 34 42.
59. 2C antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychoparmacol 2002 17 : 239 247.
60. Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ. Could agomelatine be the ideal antidepressant? Expert Rev Neurother 2006 6 : 1595 1608.
61. Zupancic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs 2006 20 : 981 992.
62. 2C receptors. Pharmacol Ther 2009 121 : 160 173.
63. 3 receptors: A role in the antidepressant response. Curr Drug Targets 2006 7 : 165 175.
64. Dremencov E, Gispan-Herman I, Rosenstein M, Mendelman A, Overstreet DH, Zohar J, Yadid G. The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: In vivo studies in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2004 28 : 141 147.
65. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull 2002 36 (Suppl 2 123 132.
66. 1A receptor activation. Eur J Pharmacol 1999 380 : R1 R3.
67. 1A receptor agonism. Brain Res 2005 1049 : 182 190.
68. 1A receptors in the rat prefrontal cortex. Eur J Pharmacol 1996 305 : 73 78.
69. 1A receptor activation. Brain Res Bull 2004 63 : 237 241.
70. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 2000 129 : 1028 1034.
71. 2-adrenergic receptors underlie its actions. Neuroscience 1999 93 : 1251 1262.
72. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000 23 : 250 262.
73. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999 38 : 315 317.
74. Amargós-Bosch M, Artigas F, Adell A. Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 2005 516 : 235 238.
75. Koch S, Perry KW, Bymaster FP. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004 46 : 232 242.
76. Gobert A, Rivet JM, Cistarelli L, Millan MJ. Buspirone enhances duloxatine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 1997 68 : 1326 1329. (Pubitemid 27086240)
77. 1A receptors in the rat frontal cortex. Neurochem Int 2002 40 : 355 360.
78. Yoshino T, Nisijima K, Shioda K, Yui K, Katoh S. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett 2004 364 : 16 21.
79. Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology 2004 176 : 195 203.
80. Ago Y, Nakamura S, Baba A, Matsuda T. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 2005 1 : 43 51.
81. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology 2006 185 : 274 281.
82. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007 191 : 745 758.
83. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiat 1991 148 : 1474 1486.
84. Svensson TH, Nomikos GG, Andersson JL. Modulation of dopaminergic neurotransmission by 5-HT2 antagonism. In : Vanhouette PM, Saxena PR, Paoletti R, Brunello N, Jackson AS, editors. Serotonin: From cell biology to pharmacology and therapeutics.
85. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 1995 15 : 11S 18S.
86. 1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 1994 116 : 143 151.
87. 1 dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 1994 71 : 515 528.
88. Meltzer HY, Nash JF. VII.Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991 43 : 587 604.
89. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001 76 : 1521 1531.
90. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990 54 : 1755 1760.
91. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 1994 115 : 147 156.
92. Hertel P, Nomikos GG, Iurlo M, Swensson TH. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 1996 124 : 74 186.
93. Volonté M, Monferini E, Cerutti M, Fodritto F, Borsini F. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 1997 69 : 182 190.
94. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999 288 : 774 781.
95. Westerink BHC, Kawahara Y, De Boer P, et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001 412 : 127 138.
96. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004 493 : 75 83.
97. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999 21 : 106S 115S.
98. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003 27 : 1159 1172.
99. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989 251 : 238 246.
100. 2A/2Creceptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002 27 : 430 441.
101. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002 947 : 157 165.
102. Ichikawa J, Meltzer HY. Amperozide, a novel antipsychotic drug, inhibits the ability of D-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 1992 58 : 2285 2291.
103. Ichikawa J, Kuroki T, Kitchen MT, Meltzer HY. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 1995 287 : 179 184.
104. Assié M-B, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005 315 : 265 272.
105. 1A receptor agonist. Part I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 2003 28 : 2064 2076.
106. 1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 2007 32 : 78 94.
107. Assié MB, Mnie-Filali O, Ravailhe V, et al. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release. Eur J Pharmacol 2009 607 : 74 83.
108. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT release in the frontal cortex in vivo. Neuropharmacology 1998 37 : 953 955.
109. Hutson PH, Barton CL, Jay M, Blurton P, Burkamp F, Clarkson R, Bristow LJ. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT2C/2B receptor antagonists: Neurochemical and behavioural studies. Neuropharmacology 2000 39 : 2318 2328.
110. 2C receptorsin vivo. Biol Psychiatry 2006 59 : 568 575.
111. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000 295 : 226 232.
112. 2C receptor. J Pharmacol Exp Ther 2001 299 : 83 89.
113. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 1999 126 : 572 574.
114. Marquis KL, Sabb AL, Logue SF, et al. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9, 10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 2007 320 : 486 496.
115. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002 71 : 555 568.
116. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic DA-ergic system. Naunyn-Schmiedeberg's Arch Phatmacol 1995 352 : 374 385.
117. 2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 2005 183 : 144 153.
118. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960 38 : 1236 1239.
119. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002 9 : 1 6.
120. Utter AA, Basso MA. The basal ganglia: An overview of circuits and function. Neurosci Biobehav Rev 2008 32 : 333 342.
121. Albin R, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989 12 : 366 375.
122. Hagan JJ, Middlemiss DN, Sharp PC, Poste GH. Parkinson's disease: Prospects for improved drug therapy. Trends Pharmacol Sci 1997 18 : 156 163.
123. Agid Y. Levodopa: Is toxicity a myth? Neurology 1998 50 : 858 863.
124. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitoxicity in Parkinson's disease: A target for neuroprotection. Ann Neurol 1998 44 (Suppl S175 S188.
125. 2C receptor be a new target for therapeutic strategies? Curr Med Chem 2006 13 : 3069 3081.
126. 1B receptors. J Pharmacol Exp Ther 2000 292 : 1111 1117.
127. 2C receptor antagonists in the treatment of Parkinson's disease? Drugs News Perspect 1999 12 : 477 483.
128. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in the human brain. Neuroscience 1999 92 : 601 611.
129. 2 receptors in adult rat brain after destruction of nigrostriatal dopamine neurons: A quantitative autoradiographic study. Brain Res 1993 606 : 273 285.
130. 2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 2000 15 : 1064 1069.
131. 2C receptor antagonists enhance the behavioural response to dopamine D1 receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur J Pharmacol 2000 398 : 59 64.
132. 2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998 151 : 35 49.
133. Spanagel R, Weiss F. The dopamine hypothesis of reward: Past and current status. Trends Neurosci 1999 22 : 521 527.
134. 3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 1989 164 : 515 519.
135. 3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 1993 230 : 63 68.
136. 3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology 2002 159 : 341 350.
137. De Deurwaerdère P, Moison D, Navailles S, Porras G, Spampinato U. Regionally and functionally distinct serotonin3 receptors control in vivo dopamine outflow in the rat nucleus accumbens. J Neurochem 2005 94 : 140 149.
138. 3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens. Pharmacol Biochem Behav 1993 45 : 759 763.
139. 3 receptor antagonist MDL 72222 dose-dependently attenuates cocaine- and amphetamine-induced elevations of extracellular dopamine in the nucleus accumbens and the dorsal striatum. Pharmacol Toxicol 1996 78 : 317 321.
140. 3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neurosci Lett 1989 101 : 214 217.
141. 3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol 1990 187 : 287 289.
142. Campbell A, Kohl R, McBride W. Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release. Alcohol 1996 13 : 569 574.
143. Campbell W, McBride WJ. Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 1995 51 : 835 842.
144. 3 receptor involvement in alcohol dependance: A microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption. Alcohol Clin Exp Res 1996 20 : 311A 319A.
145. 3 receptor antagonist. Neuropharmacology 1995 34 : 211 215.
146. Porras G, De Deurwaerdère P, Moison D, Spampinato U. Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 2003 17 : 771 781.
147. 3 receptor antagonists do not modify cocaine place conditioning or the rise in extracellular dopamine in the nucleus accumbens of rats. Pharmacol Biochem Behav 1996 55 : 33 37.
148. 1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 1999 32 : 132 135.
149. 1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J Pharmacol Exp Ther 2004 311 : 711 719.
150. 1B receptors within the ventral tegmental area in ethanol-induced increases in mesolimbic dopaminergic transmission. Brain Res 2005 1060 : 126 137.
151. 2A receptors. Eur J Pharmacol 1995 280 : R9 R11.
152. 2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4- methylenedioxymethamphetamine. Eur J Pharmacol 1992 223 : 65 74.
153. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 1996 15 : 116 124.
154. 2 receptors. Neuropsychopharmacology 2002 26 : 40 52.
155. Fletcher PJ, Korth KM, Robinson SR, Baker GB. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: Studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology 2002 162 : 282 291.
156. 2C/2Breceptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002 26 : 311 324.
157. 2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res 1998 781 : 291 299.
158. /2Bantagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 1999 20 : 556 564.
159. O'Neill MF, Heron-Maxwell CL, Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol Biochem Behav 1999 63 : 237 243.
160. 2A receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 2001 297 : 357 363.
161. 2C receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 2002 27 : 576 586.
162. Rocha BA, Goulding EH, O'Dell LE, Mead AN, Coufal NG, Parsons LH, Tecott LH. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 2002 22 : 10039 10045.
163. 2C receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther 2000 295 : 1183 1191.
164. 2C receptors in modifying ethanol self-administration behaviour. Pharmacol Biochem Behav 2002 71 : 735 744.
165. 2C receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 2001 157 : 292 298.
166. 2C receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 2004 89 : 418 429. (Pubitemid 38495990)
167. 2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration. J Pharmacol Exp Ther 2004 309 : 109 118. (Pubitemid 38393121)
168. Ungless MA, Magill PJ, Bolam JP. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 2004 303 : 2040 2042.
169. Kelland MD, Freeman AS, Chiodo LA. Chloral hydrate anaesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration. Synapse 1989 3 : 30 37.